


**Premise #1**

**What is the Most Common Cause of Morbidity and Mortality in the Industrialized World?**




Detective Adrian Monk  
© www.theDr.com 5

NIH, Autoimmune Diseases Coordinating Comm.  
Autoimmune Diseases Research Plan, 2006

NATIONAL INSTITUTE OF HEALTH  
**AUTOIMMUNE DISEASES COORDINATING**

**To provide a context to evaluate the impact of autoimmune diseases, cancer affected approximately 9 million people and heart disease affected approximately 22 million people in the United States**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
© www.theDr.com 6







Cancer	9 million people
Heart Disease	22 million people
Auto Immune Disease	24 million people

© www.theDr.com 7

The Journal of Immunology, 2005, 175: 4119-4126.

**Autoimmune diseases are the third leading cause of morbidity and mortality in the industrialized world, surpassed only by cancer and heart disease.**

© www.theDr.com 8



**Perhaps if We Open to More Current Information.....**

© www.theDr.com 13

World J Cardiol. May 26, 2014; 6(5): 314-326

**WJCI World Journal of Cardiology**

**Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity**

Nicola DiFrancesco, Fabiana Petroncini, Silvia Nardelli

**Immune-driven inflammation is key to the development of cardiovascular disease (CVD)**

© www.theDr.com 14

**Contemporary Reviews in Cardiovascular Medicine**

**Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases**

Yuhiko Shiohara, MD, FRCPC (Hans Robert Gatz, MD, Andrea DiCorleto, MD, Massimo Messori, MD, Nicola DiFrancesco, MD, Luca J. Kim, MD, Massimo DiCorleto, MD, Luigi Moretti, MD, Yuhiko Shiohara, MD)

Circulation. 2005;112:3337-3347

**Atherosclerosis is increasingly considered an immune system-mediated process of the vascular system.**

© www.theDr.com 15

**The Open Cardiovascular Medicine Journal, 2011, 5, 64-75**

**Dyslipidemia in Rheumatological Autoimmune Diseases**

Tiziana E. Toni, Valterio F. Pasquali, and George D. Kitis

**Autoimmunity plays a major role in the development of dyslipidemia and atherosclerotic plaque formation.**

© www.theDr.com 16



World J Cardiol. May 26, 2014; 6(5): 314-326

**World Journal of Cardiology**

Autoantibodies to apolipoprotein A-I as a biomarker of cardiovascular autoimmunity

Nabea Sulaiman, Fabrice Ponsot, Olivier Hantou

**Atherogenesis has been proposed to be considered an autoimmune disease, raising the hope that CVD could be prevented by immunomodulation.**

Abstract  
Atherogenesis has been proposed to be considered an autoimmune disease, raising the hope that CVD could be prevented by immunomodulation.

17

Dyslipidemia in Rheumatological Autoimmune Diseases

The Open Cardiovascular Medicine Journal, 2011, Volume 5 71

**Anti-Phospholipid Ab**  
Anti-APL  
Enhances plaque thrombosis

**Anti-Oxidative LDL Ab**  
Anti-oxLDL  
↓ small dense LDL, reduces foam cell formation

**Anti-Lipoprotein Lipase Ab**  
Anti-LPL  
↓ Lp(a) reduces plaque thrombosis

Fig. (5). Common changes in the lipid profile amongst the autoimmune rheumatic disease and their impact on atherosclerotic plaque formation. LDL: Low density lipoproteins, TG: Triglycerides, Lp(a): Lipoprotein (a), Anti-LPL: anti-Lipoprotein Lipase, HDL: high density lipoproteins, ApoA1: Apolipoprotein A1, Anti-APL: anti-phospholipid.

© www.theDr.com

18

The Open Cardiovascular Medicine Journal, 2011, 5, 64-75

**The Open Cardiovascular Medicine Journal, 2011, 5, 64-75**

Dyslipidemia in Rheumatological Autoimmune Diseases

Tracy E. Tracy<sup>1</sup>, Vladimir P. Pavlovic<sup>2</sup> and George D. Kitko<sup>1,3\*</sup>

**Autoimmunity plays a major role in the development of dyslipidemia and atherosclerotic plaque formation. The mechanisms underlying these changes include the interplay of inflammation and auto-antibody formation.**


Abstract  
Autoimmunity plays a major role in the development of dyslipidemia and atherosclerotic plaque formation. The mechanisms underlying these changes include the interplay of inflammation and auto-antibody formation.

19

**Thus, If CVD has an Initiating Autoimmune Component, Arguably, What Becomes the #1 Mechanism in the Progression of Morbidity and Mortality?**

© www.theDr.com

20



**Silently Point to 2 People Close By**

**How often do you see Autoimmune Disorders Currently in Your Practice and Given these Numbers, What Would the Impact Be IF You were Recognizing Autoimmune Disorders at this Frequency?**


Detective Adrian Monk  
© www.theDr.com 21

National Institutes of Health  
THE AUTOIMMUNE DISEASES COORDINATING COMMITTEE

**Prevention of Autoimmune Diseases:**

- Define genetic make-up of susceptible individuals
- Identify environmental triggers
- Identify autoantibodies
- Develop preventive interventions

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health  
National Institute of Allergy and Infectious Diseases



© www.theDr.com 22

The Open Cardiovascular Medicine Journal, 2011, 5, 64-75

**Dyslipidemia in Rheumatological Autoimmune Diseases**

Tommy E. Tanzi<sup>1</sup>, Vladimir P. Pavlovski<sup>2</sup> and George D. Kales<sup>1,3\*</sup>

**Abstract** Autoimmunity plays a major role in the development of dyslipidemia and atherosclerotic plaque formation. The mechanisms underlying these changes include the interplay of inflammation and auto-antibody formation.

**THERAPEUTIC TARGET**

ADDITIONAL KEYWORDS: PLASMA FIBRINOGEN, THE RISK OF CVD, AND INFLAMMATION

© www.theDr.com 23


**Intersection Of The Origin Of Autoimmune Disease**

**Inflammaging**

The overexpression of inflammation genes, immune-response genes and genes associated with the lysosomal system J Clin Immunol 29:397405, 2009

© www.theDr.com 24

**Premise #2**  
**Genes Control Function**



Detective Adrian Monk  
© www.theDr.com 25

Reproductive Toxicology 23 (2007) 297-307





Fig. 1. One-year-old female genetically identical viable yellow agouti mice ( $A^{vy}$ ). Maternal dietary supplementation with methyl donors such as folic acid, choline, and betaine [34] or the phytoestrogen, genistein [32], shifts the coat color of the offspring from yellow to brown, and reduces the incidence of obesity, diabetes, and cancer.  
© www.theDr.com 26



**Yellow   Slightly Mottled   Mottled   Heavily Mottled   Pseudo-agouti**

Figure 1. Genetically identical 3-mo-old  $A^{vy}$  mice representing the five coat color phenotypes. Yellow mice are hypomethylated at the transposable element upstream of the *Agouti* gene allowing maximal ectopic expression, whereas hypermethylation of this site silences ectopic *Agouti* expression in the pseudoagouti animals. Mice that are predominately yellow are also clearly more obese than brown mice. Reprinted from Dolinsky DC *et al.* 2006 Environ Health Perspect 114:567-572, with permission.  
**Pediatr Res. 2007;61:30R-37R.**  
© www.theDr.com 27



© www.theDr.com 28










# POTENTIAL TRIGGER

## #1

© www.theDr.com

33



Article **Am J Psychiatry 2012 ;169:625-632**

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Avi Shohmitz, M.D.  
 Susanna Wicks, Ph.D.  
 Shanyu Tang, M.Sc.  
 Richard H. Yolton, M.D.

**Abstract:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Objective:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Method:** The study included 1,000 women who reported elevated levels of antibodies to dietary antigens during pregnancy. The authors analyzed the relationship between maternal antibody levels and offspring outcomes.

**Results:** Children born to mothers with elevated levels of antibodies to dietary antigens had an increased risk for nonaffective psychosis compared to children born to mothers with lower levels of antibodies.

**Conclusion:** The authors conclude that elevated levels of antibodies to dietary antigens during pregnancy are associated with an increased risk for nonaffective psychosis in offspring.

**Keywords:** Maternal antibodies, dietary antigens, nonaffective psychosis, offspring.

This article is published in *Archives of General Psychiatry*, 2012, 69(6):625-632.

Am J Psychiatry 2012; June 2012 625

37

Indeed, ingested gluten has been proposed to have direct effects on neuronal function, a thesis supported by both clinical, and experimental studies.

Article **Am J Psychiatry 2012 ;169:625-632**

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Avi Shohmitz, M.D.  
 Susanna Wicks, Ph.D.  
 Shanyu Tang, M.Sc.  
 Richard H. Yolton, M.D.

**Abstract:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Objective:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Method:** The study included 1,000 women who reported elevated levels of antibodies to dietary antigens during pregnancy. The authors analyzed the relationship between maternal antibody levels and offspring outcomes.

**Results:** Children born to mothers with elevated levels of antibodies to dietary antigens had an increased risk for nonaffective psychosis compared to children born to mothers with lower levels of antibodies.

**Conclusion:** The authors conclude that elevated levels of antibodies to dietary antigens during pregnancy are associated with an increased risk for nonaffective psychosis in offspring.

**Keywords:** Maternal antibodies, dietary antigens, nonaffective psychosis, offspring.

This article is published in *Archives of General Psychiatry*, 2012, 69(6):625-632.

Am J Psychiatry 2012; June 2012 625

38

IgG is actively transported across the placenta during the later stages of pregnancy to provide passive immunization of the fetus, and hence such antibodies reflect maternal exposures and immune responses to specific antigens.

Article **Am J Psychiatry 2012 ;169:625-632**

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Avi Shohmitz, M.D.  
 Susanna Wicks, Ph.D.  
 Shanyu Tang, M.Sc.  
 Richard H. Yolton, M.D.

**Abstract:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Objective:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Method:** The study included 1,000 women who reported elevated levels of antibodies to dietary antigens during pregnancy. The authors analyzed the relationship between maternal antibody levels and offspring outcomes.

**Results:** Children born to mothers with elevated levels of antibodies to dietary antigens had an increased risk for nonaffective psychosis compared to children born to mothers with lower levels of antibodies.

**Conclusion:** The authors conclude that elevated levels of antibodies to dietary antigens during pregnancy are associated with an increased risk for nonaffective psychosis in offspring.

**Keywords:** Maternal antibodies, dietary antigens, nonaffective psychosis, offspring.

This article is published in *Archives of General Psychiatry*, 2012, 69(6):625-632.

Am J Psychiatry 2012; June 2012 625

39

A significantly elevated risk for nonaffective psychoses was associated with high levels (90th percentile) of IgG anti-gliadin antibodies (odds ratio=1.7), but not anti-casein antibodies (odds ratio=0.8).

Article **Am J Psychiatry 2012 ;169:625-632**

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Avi Shohmitz, M.D.  
 Susanna Wicks, Ph.D.  
 Shanyu Tang, M.Sc.  
 Richard H. Yolton, M.D.

**Abstract:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Objective:** The authors analyzed an observational study of children born to mothers with elevated levels of antibodies to dietary antigens (gluten, casein, and soy) during pregnancy. Results suggest that elevated levels of these antibodies are associated with an increased risk for nonaffective psychosis in offspring.

**Method:** The study included 1,000 women who reported elevated levels of antibodies to dietary antigens during pregnancy. The authors analyzed the relationship between maternal antibody levels and offspring outcomes.

**Results:** Children born to mothers with elevated levels of antibodies to dietary antigens had an increased risk for nonaffective psychosis compared to children born to mothers with lower levels of antibodies.

**Conclusion:** The authors conclude that elevated levels of antibodies to dietary antigens during pregnancy are associated with an increased risk for nonaffective psychosis in offspring.

**Keywords:** Maternal antibodies, dietary antigens, nonaffective psychosis, offspring.

This article is published in *Archives of General Psychiatry*, 2012, 69(6):625-632.

Am J Psychiatry 2012; June 2012 625

40

The risk for future nonaffective psychosis increased further with levels of anti-gliadin antibodies at the 95th percentile (odds ratio=2.5)

Am J Psychiatry 2012 ;169:625-632

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Rui Shaochun, M.D.  
 Susanna Wicko, Ph.D.  
 Shanyu Tang, M.Sc.  
 Robert S. Kaplan, M.D.

**We did not find an association with antibodies to casein, suggesting that the risk is not associated with an overall increase in antibodies to food antigens.**

**A** number of adverse exposures to stress or to the environment have been associated with the later development of schizophrenia and other nonaffective psychoses. These include exposure to maternal malnutrition, infections and complications of pregnancy and birth (1). The mechanisms underlying these associations are unknown, and a variety of hypotheses have been tested experimentally. One hypothesis is that exposure to stress and nutritional deficits during fetal development and neonatal development leads to hyperactive and exaggerated responses to adult antigens (2). Indeed, reports of an elevated risk for schizophrenia among offspring of women with high blood levels of immunoglobulin G (IgG) directed at gliadin (3) and the fetus development of schizophrenia (4) have been reported. In a family longitudinal study by Egan et al. (5), individuals with elevated immunoglobulin G (IgG) directed at gliadin during the first trimester of pregnancy to possible perinatal immunotoxicity of the fetus (5), and those with antibodies to other wheat antigens and immune responses to specific antigens. Using dried blood spots obtained from newborns, we investigated whether levels of IgG directed at food-derived

41

Am J Psychiatry 2012 ;169:625-632

**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Rui Shaochun, M.D.  
 Susanna Wicko, Ph.D.  
 Shanyu Tang, M.Sc.  
 Robert S. Kaplan, M.D.

**The risk associated with high levels of IgG anti-gliadin antibodies appears to act independently of maternal age, immigration, and mode of delivery.**

**A** number of adverse exposures to stress or to the environment have been associated with the later development of schizophrenia and other nonaffective psychoses. These include exposure to maternal malnutrition, infections and complications of pregnancy and birth (1). The mechanisms underlying these associations are unknown, and a variety of hypotheses have been tested experimentally. One hypothesis is that exposure to stress and nutritional deficits during fetal development and neonatal development leads to hyperactive and exaggerated responses to adult antigens (2). Indeed, reports of an elevated risk for schizophrenia among offspring of women with high blood levels of immunoglobulin G (IgG) directed at gliadin (3) and the fetus development of schizophrenia (4) have been reported. In a family longitudinal study by Egan et al. (5), individuals with elevated immunoglobulin G (IgG) directed at gliadin during the first trimester of pregnancy to possible perinatal immunotoxicity of the fetus (5), and those with antibodies to other wheat antigens and immune responses to specific antigens. Using dried blood spots obtained from newborns, we investigated whether levels of IgG directed at food-derived

42

Am J Psychiatry 2012 ;169:625-632


**Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring**

Hilary Korfman, Ph.D.  
 Rui Shaochun, M.D.  
 Susanna Wicko, Ph.D.  
 Shanyu Tang, M.Sc.  
 Robert S. Kaplan, M.D.

**The bulk of fetal IgG is transferred from the mother during the last 4 weeks of the pregnancy.**

**A** number of adverse exposures to stress or to the environment have been associated with the later development of schizophrenia and other nonaffective psychoses. These include exposure to maternal malnutrition, infections and complications of pregnancy and birth (1). The mechanisms underlying these associations are unknown, and a variety of hypotheses have been tested experimentally. One hypothesis is that exposure to stress and nutritional deficits during fetal development and neonatal development leads to hyperactive and exaggerated responses to adult antigens (2). Indeed, reports of an elevated risk for schizophrenia among offspring of women with high blood levels of immunoglobulin G (IgG) directed at gliadin (3) and the fetus development of schizophrenia (4) have been reported. In a family longitudinal study by Egan et al. (5), individuals with elevated immunoglobulin G (IgG) directed at gliadin during the first trimester of pregnancy to possible perinatal immunotoxicity of the fetus (5), and those with antibodies to other wheat antigens and immune responses to specific antigens. Using dried blood spots obtained from newborns, we investigated whether levels of IgG directed at food-derived

43





Am J Psychiatry 2012 ;169:625-632

Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring

Wolke, M. E., et al.

**A mechanism potentially linking maternal anti gliadin reactivity with the later development of psychosis in offspring involves maternal inflammation.**

Abstract: The authors studied 1,000 children born to mothers with high levels of anti gliadin antibodies (IgA) during an immune response against wheat gluten. They found that children born to these mothers had a higher risk of developing psychosis later in life compared to children born to mothers with low levels of anti gliadin antibodies. This finding suggests that maternal inflammation during pregnancy may play a role in the development of psychosis in offspring.

45

So What is the Clinical Relevance of This?  
How Do I Use This Information in My Practice?

© www.theDr.com

46

EVERY PREGNANT WOMAN IS ACCURATELY TESTED FOR A GLUTEN RELATED DISORDER, NOT JUST CELIAC DISEASE

© www.theDr.com

47

Latent celiac disease in reproductive performance of women

Fertility and Sterility Vol. 95, No. 3, March 1, 2011

**The seroprevalence of transglutaminase IgA was 6.70% in the group with recurrent abortion, 5.70% in the group with stillbirth, 5.65% in the group with infertility, 9.33% in the group with intrauterine growth restriction, and 1.30% in the control group.**

Abstract: The authors studied 1,000 women with reproductive issues. They found that 6.70% of women with recurrent abortion, 5.70% of women with stillbirth, 5.65% of women with infertility, 9.33% of women with intrauterine growth restriction, and 1.30% of women in the control group had latent celiac disease. This finding suggests that latent celiac disease may be associated with reproductive issues.

© www.theDr.com

48



**Am J Clin Nutr. 2007;85:1417-1427**

This correspondence referred to page 1417.

**Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENT Study<sup>1-4</sup>**

Priscilla Kraloff, Marjolijn Bakkerman, David J. Goodman, Jani Kallioinen, Taina Salonen, Katherine Swanson, Loren Pechlivan, Glenn M. Eckelstein, Carol M. Lusk, and David J. Freedman

**ABSTRACT** Background: Diet with a high glycemic load may contribute to the pathogenesis of the metabolic syndrome, associated abnormalities include abdominal obesity, insulin resistance, and dyslipidemia. We hypothesized that a diet with a low glycemic load would improve these abnormalities in persons with the metabolic syndrome.

**OBJECTIVE:** We tested the hypothesis that a diet with a low glycemic load would improve these abnormalities in persons with the metabolic syndrome.

**DESIGN:** Randomized controlled trial.

**SETTING:** University of Colorado Health Sciences Center, Denver, Colorado.

**PARTICIPANTS:** Persons with the metabolic syndrome.

**MEASUREMENTS AND MAIN RESULTS:** We randomized 20 persons with the metabolic syndrome to a diet with a high glycemic load (HGL) or a diet with a low glycemic load (LGL) for 12 weeks. The LGL diet significantly improved abdominal obesity, insulin resistance, and dyslipidemia compared with the HGL diet.

**CONCLUSIONS:** A diet with a low glycemic load improves abdominal obesity, insulin resistance, and dyslipidemia in persons with the metabolic syndrome.

53

**In contrast, the 12-week oat-wheat-potato diet upregulated 62 genes related to stress, cytokine-chemokine-mediated immunity, and the interleukin pathway.**

**Am J Clin Nutr. 2007;85:1417-1427**

This correspondence referred to page 1417.

**Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENT Study<sup>1-4</sup>**

Priscilla Kraloff, Marjolijn Bakkerman, David J. Goodman, Jani Kallioinen, Taina Salonen, Katherine Swanson, Loren Pechlivan, Glenn M. Eckelstein, Carol M. Lusk, and David J. Freedman

**ABSTRACT** Background: Diet with a high glycemic load may contribute to the pathogenesis of the metabolic syndrome, associated abnormalities include abdominal obesity, insulin resistance, and dyslipidemia. We hypothesized that a diet with a low glycemic load would improve these abnormalities in persons with the metabolic syndrome.

**OBJECTIVE:** We tested the hypothesis that a diet with a low glycemic load would improve these abnormalities in persons with the metabolic syndrome.

**DESIGN:** Randomized controlled trial.

**SETTING:** University of Colorado Health Sciences Center, Denver, Colorado.

**PARTICIPANTS:** Persons with the metabolic syndrome.

**MEASUREMENTS AND MAIN RESULTS:** We randomized 20 persons with the metabolic syndrome to a diet with a high glycemic load (HGL) or a diet with a low glycemic load (LGL) for 12 weeks. The LGL diet significantly improved abdominal obesity, insulin resistance, and dyslipidemia compared with the HGL diet.

**CONCLUSIONS:** A diet with a low glycemic load improves abdominal obesity, insulin resistance, and dyslipidemia in persons with the metabolic syndrome.

54

**The insulinogenic index improved after the rye-pasta diet (P = 0.004) but not after the oat-wheat-potato diet.**

**JAMA Pediatr. 2013;167(4):374-379**

REVIEW ARTICLE

**Effect of Intestinal Microbial Ecology on the Developing Brain**

Manika Pringle-Foster, MD, Elizabeth E. Foster, PhD, Joel D. Klein, MD

**T**he mammalian gastrointestinal tract harbors a highly diverse microbial population that plays a major role in nutrition, metabolism, protection against pathogens, and development of the immune system. It is estimated that at least 1000 different bacterial species inhabit the human gut.

**THE GUT MICROBIOME**

**Metabolic Risk**

Although often thought of as pathogenic, the vast majority of gut bacteria are commensal. These commensal bacteria are essential for the development of the immune system. In the human gut, they are directly involved in regulating immune and metabolic responses. Emerging data suggest that the composition of the gut microbiome is altered in persons with obesity, insulin resistance, and type 2 diabetes. These changes are associated with increased risk of these conditions.

**CONCLUSIONS**

The gut microbiome is a complex ecosystem that plays a major role in the development of the immune system and metabolism. Alterations in the gut microbiome are associated with increased risk of obesity, insulin resistance, and type 2 diabetes. Further research is needed to understand the mechanisms underlying these associations.

55

**The interaction between the gastrointestinal cells and the commensal bacteria fosters immunological tolerance, whereas the interaction with pathogens triggers inflammatory responses.**

**JAMA Pediatr. 2013;167(4):374-379**

REVIEW ARTICLE

**Effect of Intestinal Microbial Ecology on the Developing Brain**

Manika Pringle-Foster, MD, Elizabeth E. Foster, PhD, Joel D. Klein, MD

**T**he mammalian gastrointestinal tract harbors a highly diverse microbial population that plays a major role in nutrition, metabolism, protection against pathogens, and development of the immune system. It is estimated that at least 1000 different bacterial species inhabit the human gut.

**THE GUT MICROBIOME**

**Metabolic Risk**

Although often thought of as pathogenic, the vast majority of gut bacteria are commensal. These commensal bacteria are essential for the development of the immune system. In the human gut, they are directly involved in regulating immune and metabolic responses. Emerging data suggest that the composition of the gut microbiome is altered in persons with obesity, insulin resistance, and type 2 diabetes. These changes are associated with increased risk of these conditions.


**CONCLUSIONS**

The gut microbiome is a complex ecosystem that plays a major role in the development of the immune system and metabolism. Alterations in the gut microbiome are associated with increased risk of obesity, insulin resistance, and type 2 diabetes. Further research is needed to understand the mechanisms underlying these associations.

56

**This cross talk between microbiota and gut mucosal cells (enterocytes, dendritic cells, lymphocytes, macrophages, and M cells) regulates the production of various cytokines and chemokines. These can be proinflammatory, such as IL-8 and IL-1, or anti-inflammatory, such as IL-10 and transforming growth factor.**





**Although there are many contributors to systemic inflammation, there is 1 that is extremely common in most autoimmune diseases**

© www.theDr.com 58

**Premise #4**

**Where Does the Persisting Inflammation Come From?**

© www.theDr.com 59

**Amgen Award Lecture** Amer Jour of Path, Vol. 169, No. 6, Dec 2006

Molecular Basis of Epithelial Barrier Regulation  
From Basic Mechanisms to Clinical Application

**One critical function of epithelial-lined surfaces is to define the interface between separate body compartments.**

© www.theDr.com 60

Amgen Award Lecture **Amer Jour of Path, Vol. 169, No. 6, Dec 2006**

Molecular Basis of Epithelial Barrier Regulation  
From Basic Mechanisms to Clinical Application

**Examples include the skin, which maintains a barrier that supports overall homeostasis and prevents systemic infection, and the renal tubule, which forms a barrier that maintains gradients between the renal interstitium and the sterile tubular lumen to allow active and passive transport to regulate urine composition**

© www.theDr.com 61

Amgen Award Lecture **Amer Jour of Path, Vol. 169, No. 6, Dec 2006**

Molecular Basis of Epithelial Barrier Regulation  
From Basic Mechanisms to Clinical Application

**The intestinal mucosa has a far more difficult charge: it must balance the needs for a barrier against a hostile environment, like the skin, with the necessity of active and passive transport, like the renal tubule. An intact intestinal barrier is, therefore, critical to normal physiological function and prevention of disease.**

© www.theDr.com 62

GASTROENTEROLOGY CLINICS OF NORTH AMERICA

**Celiac Disease and Autoimmunity in the Gut and Elsewhere**

Susan H. Barton, MD, Joseph ... **Gastroenterol Clin N Am 37 (2008) 411-428**

**Proposed mechanisms of association (in AID development) include abnormal regulation of intestinal permeability and increased autoantibody production in the setting of chronic gut inflammation.**


© www.theDr.com 63

Brought to you by theDr.com

**The Gluten Summit**

A Grain of Truth

© www.theDr.com 64




**Alessio Fasano, MD**  
Currently Chairs Harvard's Mass General  
Hospital for Children where he heads the  
Department of Pediatric Gastroenterology

**Why Creating the Healthiest Intestinal Environment Possible Can  
Arrest Your Vulnerability to the #3 Cause of Getting Sick and Dying**

- Understanding autoimmunity and gluten sensitivity
- The evolution of wheat and gluten
- Epigenetics and the development of disease
- The three mechanisms that contribute to autoimmunity
- What triggers celiac disease?
- Why no human can digest gluten


© www.theDr.com 65



**Alessio Fasano, MD**

**Dr. Fasano, Could you tell us, what is the importance of  
pathogenic intestinal permeability?**


© www.theDr.com 66



**Alessio Fasano, MD**

*It's one of the key functions of the intestine that I probably  
think has been **the most overlooked** over human biology. So,  
we always were under the impression that the key function of  
the intestine is to digest and absorb foodstuffs. And, that, of  
course, is an important function. But, it's not just that. It's  
much more than that.*

© www.theDr.com 67



**Alessio Fasano, MD**

*If we just pay attention to what nature has done in  
engineering this wonderland system that is the gut's  
intestinal system, **you start to wonder why** the anatomy and  
the physiology is built in that way. And, you start to see, the  
amplified surface. That means we want to interface with the  
environment as much as we can.*

© www.theDr.com 68



### Intestine: Interesting Facts

~20 ft long

~3,000 sf!!!

Small Intestine

Large Intestine

© www.theDr.com

Alessio Fasano, MD

*And, again, the simplistic interpretation is that we want to digest and absorb in an efficient way the foodstuff that comes through. But, also, you start to see the fact that it is a single-layer cell, that just underneath that, the most sophisticated and abundant immune component in our body. And, then you start to see there is a very sophisticated neuroendocrine network to control all this.*

© www.theDr.com 70

Alessio Fasano, MD

*And, when you put all this together, when you connect the dots, you start to wonder, “Well, **what else** besides digesting and absorbing foodstuffs is the intestine doing?”*

© www.theDr.com 71

Alessio Fasano, MD

*The **key function is to interface** with the environment and eventually exchange information, including molecules from the environment.*


© www.theDr.com 72



Alessio Fasano, MD

*And, the bottom line, the modern biology seems to suggest that **the state of health or the state of disease is the combination between what we are-meaning what genetically makes us, the way that we're engineered--and the environment that's around us.***


© www.theDr.com 73



Alessio Fasano, MD

*And, the gut is the point of entry in which these two elements, they really meet. And, the way that, again, this exchange happens, it really is totally controlled by the permeability of the gut. They allow--if and when allowed--molecules to come through. And, on a specific genetic background, this brings us to the outcome of the overall picture of what, biologically, we are.*


© www.theDr.com 74



Alessio Fasano, MD

*And, if everything goes fine and this traffic is tightly controlled...And, again if you look at what nature did, you realize that this is an extremely important function of this intestinal permeability, we stay in a state of health. But, if this tightly-controlled trafficking is, for whatever reason, jeopardized because of an infection, because of a change of the composition of bacteria in our gut--i.e. dysbiosis because we're abusing antibiotics--because, again, we're exposed to pollutants, chemicals, or genetically engineered foodstuffs, in other words, stuff that (will cause) dysfunction, **we will pay a price.***

© www.theDr.com 75




Alessio Fasano, MD

***"The state of health or the state of disease is the combination between what we are-meaning what genetically makes us the way that we're engineered--and the environment that's around us"**.*

© www.theDr.com 76

Alessio Fasano, MD



*So, with Intestinal Permeability, we don't have this tightly-controlled trafficking anymore. But, this uncontrolled trafficking of these molecules. And, depending who we are, on what kind of genetic background we have, we can develop different problems.*

© www.theDr.com 77

Alessio Fasano, MD



*For example, we can develop food allergies if we are skewed to develop **allergies**. We can develop **autoimmune diseases**. We can develop chronic inflammation that can lead to **a stroke, Alzheimer's**, you name it, **cancer**. And, all this depends, again, on who we are genetically speaking, and what kind of environment is surrounding us.*

© www.theDr.com 78


Alessio Fasano, MD



*So, I think that to make this in even more in simple terms, when we're born, and, therefore, we have the entire genetic potentials, we are like a very precious single marble block. But, what is going to end up on this marble block in terms of what kind of sculpture, it depends on the environment. So, it can be an environment that you can become the painter Michelangelo's David.*




© www.theDr.com 79

Alessio Fasano, MD



*Or, you can be in a different environment and the outcome will not be so wonderful. And, that's pretty much the story.*

© www.theDr.com 80



**A Special Gift For You!**

I'm going to send you  
3 take-aways to help you implement this information!

Access to the 49 research articles used to create this presentation! plus

“The Conundrum of Gluten Sensitivity”

“Differentiating Gluten Related Disorders”

“US Perspective on gluten-related diseases”


Top two written by Dr. Thomas O'Bryan DC, CCN, DACBN  
And 1 written by the Center for Celiac Research at Harvard

© www.theDr.com 84





## Get Out Your Phones



- **Use the references:**
  - **For your personal review to increase your knowledge about the connection between food sensitivities and autoimmunity**
  - **Share them with your patients, family, friends and Loved Ones**
  - **Share with your peers, your Study Groups, and begin the discussion with them as to how these research topics may relate to your Practices**





© www.theDr.com

87



Text to:

**58885**



🗨️

**Text to:**


# 58885

**(Gluten and your email address)**


**to receive your  
the References and Articles from me!**

© www.theDr.com 93

## Premise #5 What is the Impact of Intestinal Permeability?



© www.theDr.com 94



REVIEW

Mucosal Immunology | VOLUME 3 NUMBER 3 | MAY 2010

Multiple facets of intestinal permeability and epithelial handling of dietary antigens

A Minireview by Scott Bressanese and M. Hershkovitz

**Increased intestinal permeability is an early biological change that often precedes the onset of autoimmune diseases. Such increased permeability could be due to environmental factors (such as infection, toxic molecules, allergenic foods) that possibly initiate the (autoimmune) disease.**

© www.theDr.com 96

148

COMMENTARIES

**Life and death in the gut: more killing, less Crohn's**  
A. Stoen, C. Fiocchi

The beneficial effects of inflammation, the tumor necrosis factor antibody, in Crohn's disease may be mediated by synthesis of activated natural T cells

**Abstract**  
The presence of an inflammatory response in the intestine is a hallmark of Crohn's disease. In Crohn's disease, the immune system is overactive, leading to chronic inflammation and tissue damage. This inflammation is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response. This imbalance is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response. This imbalance is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response.

**Introduction**  
The presence of an inflammatory response in the intestine is a hallmark of Crohn's disease. In Crohn's disease, the immune system is overactive, leading to chronic inflammation and tissue damage. This inflammation is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response. This imbalance is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response.

**Conclusion**  
The presence of an inflammatory response in the intestine is a hallmark of Crohn's disease. In Crohn's disease, the immune system is overactive, leading to chronic inflammation and tissue damage. This inflammation is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response. This imbalance is thought to be driven by an imbalance of the immune response, with an overactive Th1 response and a suppressed Th2 response.

© www.theDr.com 97

There is a constant state of balanced chronic inflammation present in the gastrointestinal tract. This physiologic inflammation is essential for the maturing of the immune system and development of the normal morphology of the intestinal mucosa.

149

REVIEW

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**  
Abbas Fares\* and Tessa Oles-Ducharme

**Abstract**  
The primary functions of the gastrointestinal tract have traditionally been perceived to be limited to the digestion and absorption of nutrients and electrolytes, and to water homeostasis.

**Introduction**  
The primary functions of the gastrointestinal tract have traditionally been perceived to be limited to the digestion and absorption of nutrients and electrolytes, and to water homeostasis. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

**Conclusion**  
The primary functions of the gastrointestinal tract have traditionally been perceived to be limited to the digestion and absorption of nutrients and electrolytes, and to water homeostasis. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

© www.theDr.com 98

The primary functions of the gastrointestinal tract have traditionally been perceived to be limited to the digestion and absorption of nutrients and electrolytes, and to water homeostasis.

150

REVIEW

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**  
Abbas Fares\* and Tessa Oles-Ducharme

**Abstract**  
A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.

**Introduction**  
A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

**Conclusion**  
A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

© www.theDr.com 99

A more attentive analysis of the anatomic and functional arrangement of the gastrointestinal tract, however, suggests that another extremely important function of this organ is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.

151

REVIEW

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**  
Abbas Fares\* and Tessa Oles-Ducharme

**Abstract**  
The classical paradigm of autoimmune pathogenesis involving a specific genetic makeup and exposure to environmental triggers has been challenged by the addition of a third element: the loss of intestinal barrier function.

**Introduction**  
The classical paradigm of autoimmune pathogenesis involving a specific genetic makeup and exposure to environmental triggers has been challenged by the addition of a third element: the loss of intestinal barrier function. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

**Conclusion**  
The classical paradigm of autoimmune pathogenesis involving a specific genetic makeup and exposure to environmental triggers has been challenged by the addition of a third element: the loss of intestinal barrier function. This review discusses the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases.

© www.theDr.com 100

The classical paradigm of autoimmune pathogenesis involving a specific genetic makeup and exposure to environmental triggers has been challenged by the addition of a third element: the loss of intestinal barrier function.



**REVIEW**  
mechanisms of disease

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**

Alvinia Farnesi\* and Tracy Shea Dushbar

**KEYWORDS** NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9

**The gut as a barrier**  
The gut is the largest immunocompetent organ in the body. It is the site of the first contact with the environment and is the site of the first contact with the immune system. It is the site of the first contact with the immune system. It is the site of the first contact with the immune system.

**REVIEW OBJECTIVES**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**KEY POINTS**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**REFERENCES**  
1. Farnesi A, Dushbar TS. Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2(9): 500-508.

© www.theDr.com

101

Together with the gut-associated lymphoid tissue and the neuroendocrine network, the intestinal epithelial barrier, with its intercellular tight junctions, controls the equilibrium between tolerance and immunity to nonself-antigens.

**REVIEW**  
mechanisms of disease

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**

Alvinia Farnesi\* and Tracy Shea Dushbar

**KEYWORDS** NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9

**The gut as a barrier**  
The gut is the largest immunocompetent organ in the body. It is the site of the first contact with the environment and is the site of the first contact with the immune system. It is the site of the first contact with the immune system. It is the site of the first contact with the immune system.

**REVIEW OBJECTIVES**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**KEY POINTS**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**REFERENCES**  
1. Farnesi A, Dushbar TS. Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2(9): 500-508.

© www.theDr.com

102

When the finely tuned trafficking of macromolecules is dysregulated in genetically susceptible individuals, both intestinal and extraintestinal autoimmune disorders can occur.

**REVIEW**  
mechanisms of disease

**Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases**

Alvinia Farnesi\* and Tracy Shea Dushbar

**KEYWORDS** NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9

**The gut as a barrier**  
The gut is the largest immunocompetent organ in the body. It is the site of the first contact with the environment and is the site of the first contact with the immune system. It is the site of the first contact with the immune system. It is the site of the first contact with the immune system.

**REVIEW OBJECTIVES**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**KEY POINTS**  
The objectives of this review are to discuss the role of the intestinal barrier in the pathogenesis of gastrointestinal autoimmune diseases. It will also discuss the role of the immune system in the pathogenesis of these diseases.

**REFERENCES**  
1. Farnesi A, Dushbar TS. Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. *Nat Clin Pract Gastroenterol Hepatol* 2005; 2(9): 500-508.


© www.theDr.com

103

The autoimmune process can be arrested if the interplay between genes and environmental triggers is prevented by re-establishing intestinal barrier function.

**Premise #6**

**What is the Mechanism of Intestinal Permeability?**



104

**CLIN GASTRO AND HEP 2012;10:1096-1100**

**ADVANCES IN TRANSLATIONAL SCIENCE**

Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications

ALESSIO FALASCO

Molecular Biology Research Center and Institute for Value Research, University of Modena and Reggio Emilia, Modena, Italy

**Among the several potential intestinal stimuli that can trigger zonulin release, small intestinal exposure to bacteria (its byproduct LPS) and gluten are the 2 triggers that have been identified so far.**

**What Are the Findings?**  
Regulation of Intestinal Permeability: The Zonulin Pathway

© www.theDr.com 105

**REVIEW**



Mechanisms of Disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases





Alejandra Fariñas<sup>1</sup> and Steven D. Dharwadkar

**REVIEW** **NAT CLIN PRAC GASTRO & HEP SEPT 2005 VOL 2 NO 9**

**An extremely important function of the GI Tract is its ability to regulate the trafficking of macromolecules between the environment and the host through a barrier mechanism.**

© www.theDr.com 106





SHOCK, Vol. 30, No. 10, pp. 90-96, 2008

**Shock. 2009 Oct;32(4):374-8**

**SYSTEMIC INFLAMMATION INCREASES INTESTINAL PERMEABILITY DURING EXPERIMENTAL HUMAN ENDOTOXAEMIA**

Falko Hübner,<sup>1</sup> Marc G.H. Besselink,<sup>1</sup> Willem Reijnen,<sup>1</sup> Martin B.M. de Smit,<sup>1</sup> Arieboon Linares,<sup>1</sup> Hans van der Fliet,<sup>1</sup> and Pieter Pickard<sup>2</sup>

<sup>1</sup>Department of Surgery, University Medical Center Utrecht, Utrecht and <sup>2</sup>Department of Internal Care Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Received 12 Mar 2008; final version accepted 19 Jul 2008; accepted 4 Nov 2008; first published online 10 Dec 2008

**Abstract**—Although the gut is often considered the main or even the major barrier between systemic inflammation and intestinal permeability in humans in vivo, the original barrier properties have been questioned in patients with Crohn's disease and in mice during experimental endotoxaemia. We investigated whether systemic inflammation in humans is associated with an increase in intestinal permeability during experimental endotoxaemia. We used a validated permeability test (Lactulose/Mannitol ratio) to measure intestinal permeability in 10 healthy subjects before and after a 2-h intravenous infusion of endotoxin (LPS). Systemic inflammation was induced by LPS. The LPS infusion significantly increased the Lactulose/Mannitol ratio (P < 0.05). Systemic inflammation results in an increased intestinal permeability in vivo.

**Key words:** endotoxaemia, intestinal permeability, inflammation, LPS, Lactulose/Mannitol ratio

**Introduction**—The gut is often considered the main or even the major barrier between systemic inflammation and intestinal permeability in humans in vivo. The original barrier properties have been questioned in patients with Crohn's disease and in mice during experimental endotoxaemia. We investigated whether systemic inflammation in humans is associated with an increase in intestinal permeability during experimental endotoxaemia. We used a validated permeability test (Lactulose/Mannitol ratio) to measure intestinal permeability in 10 healthy subjects before and after a 2-h intravenous infusion of endotoxin (LPS). Systemic inflammation was induced by LPS. The LPS infusion significantly increased the Lactulose/Mannitol ratio (P < 0.05). Systemic inflammation results in an increased intestinal permeability in vivo.

**Materials and Methods**—Ten healthy subjects were included in the study. The subjects received a 2-h intravenous infusion of endotoxin (LPS) (1 µg kg<sup>-1</sup> h<sup>-1</sup>). The Lactulose/Mannitol ratio was measured before and after the infusion. The Lactulose/Mannitol ratio was significantly increased after the infusion (P < 0.05).


**Conclusion**—Systemic inflammation results in an increased intestinal permeability in humans in vivo.

© www.theDr.com

113

**Premise #7**

**Immunological Markers in Screening for Antigenic Intestinal Permeability**



Mucosal Immunology Vol 3 No 3 | MAY 2010  
 Neuroendocrinology Letters Volume 29 No. 1 2008  
 J Affect Disord. 2007 Apr;99(1-3):237-40 © www.theDr.com  
 Neuro Endocrinol Lett. 2007 Dec;28(6):739-44.

114

**Immunological Markers in Screening for Antigenic Intestinal Permeability**

**BLOOD**


Autoimmunity of Tight Junctions

Occludin / Zonulin  
 IgG, IgM, IgA

© www.theDr.com

115

Ann. N.Y. Acad. Sci. 1165: 195-205 (2009)



© www.theDr.com

116



Scand J of Gastro, 2006; 41: 408/419


**Gliadin, zonulin and gut permeability: Effects on celliac and non-celliac intestinal mucosa and intestinal cell lines**

SANDRO DRAGO<sup>1,2</sup>, RAJZI EL ASSAR<sup>1</sup>, MARIANORA DE PIERRO<sup>3,4</sup>, MARIA GRACIA CLEMENTE<sup>1</sup>, AMIT TRIPATHI<sup>1</sup>, ANNA KAPONE<sup>1</sup>, MANUELA THARAL<sup>1</sup>, GIUSEPPE IACONI<sup>1</sup>, ANTONIO CARROCCIO<sup>1</sup>, CINZIA D'AMALDI<sup>1</sup>, TARCISIO SOTTI<sup>1</sup>, LUCIA ZAMPINI<sup>1</sup>, CARLO CATARZI<sup>1,2</sup> & ALESSIO FASANI<sup>1</sup>

**Gliadin activates the zonulin signaling, resulting in immediate reduction of intestinal barrier function and passage of gliadin into the subepithelial compartment.**

**Key Words:** Celiac disease, gliadin, gut permeability, tight junctions, zonulin

117



Scand J of Gastro, 2006; 41: 408/419

**Control**      **PT-gliadin**

**Figure 2. Effect of gliadin on intestinal epithelial cells cytoskeleton leads to a reorganization of actin filaments**

© www.theDr.com





119


Ann. N.Y. Acad. Sci. 1165: 195-205 (2009).

**The rearrangement of the filaments of actin and the subsequent displacement of proteins (including ZO-1) from the junctional complex**


© www.theDr.com

120






### How does the Passage of LPS into the blood stream occur?



- through the oral cavity (gingivitis, periodontitis)
- through an open wound
- septicemia
- lipid raft transcytosis
- pathogenic Intestinal Permeability

© www.theDr.com 126





The Journal of Immunology, 2006, 176: 2512-2521

Glutelin Stimulation of Murine Macrophage Inflammatory Gene Expression and Intestinal Permeability Are MyD88-Dependent: Role of the Innate Immune Response in Celiac Disease?

Karen E. Thomson,<sup>1</sup> Anna Sapone,<sup>2</sup> Aleksa Frazee,<sup>1</sup> and Stefano N. Vignani<sup>1,2</sup>

Recent studies have demonstrated the importance of TLR signaling in intestinal homeostasis. T-like disease (TD) is an autoimmune enteropathy thought to originate primarily in the mucosa of the gastrointestinal tract. In this study, we sought to test the hypothesis that the innate immune response, specifically MyD88-dependent signaling, is involved in the pathogenesis of TD. We found that TD patients have increased expression of MyD88-dependent genes in the gut mucosa and that this expression is associated with increased intestinal permeability. In TD patients, we found that the innate immune response is upregulated in the gut mucosa and that this upregulation is associated with increased intestinal permeability. These findings suggest that the innate immune response, specifically MyD88-dependent signaling, is involved in the pathogenesis of TD. © www.theDr.com 128

**The increased permeability, which occurs within 36 hrs (of exposure to the toxic gluten proteins in wheat) seems to be a very early response to gluten exposure...**



**Inflammation and Leaky Gut: A Primary Pathway and Therapeutic Target**

**Immune Response to Intestinal Antigen Presentation**

- Intestinal Inflammation from antigen delivery (eating food)
- Loosening tight junction barrier proteins
- Antibody production to Barrier Proteins (zonulin, actomyosin)
- Leaky or Leaking gut, brain, bladder,...
- Intestinal Permeability (BBB permeability,...)
- Antigen translocation
- Antibody Production to antigen (gluten, dairy,...)
- Molecular Mimicry (Cross Reactivity)
- Autoimmune Syndromes

Neuroendocrinology Letters Volume 29 No. 1 © www.theDr.com

**Shock, 2009 Oct;32(4):374-8**

**SYSTEMIC INFLAMMATION INCREASES INTESTINAL PERMEABILITY DURING EXPERIMENTAL HUMAN ENDOTOXEMIA**

Felix Heitkamp<sup>1</sup>, Marc G.H. Bessink<sup>1</sup>, Willem H. Gisbertz<sup>1</sup>, Martin B.M. de Smet<sup>1</sup>, Aron D. Driessens<sup>1</sup>, Hans van der Hoven<sup>1</sup>, and Peter F. de Vos<sup>1</sup>

**We demonstrated a correlation between the degree of systemic inflammation and an increase in intestinal permeability.**

132



**Physiol Rev 91: 151-175, 2011**

**Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer**

PIRELLA FERRARO  
Research Fellow, Research Center and Center for Cellular Research, University of Maryland School of Medicine, Baltimore, Maryland

**Once gluten is removed from the diet, serum zonulin levels decrease, the intestine resumes its baseline barrier function, the autoantibody titers are normalized, the autoimmune process shuts off and, consequently, the intestinal damage (that represents the biological outcome of the autoimmune process) heals completely.**

Several authors, including the only physiological modulation of zonulin in the gut is achieved by withdrawal of mucosal barrier and disruption of intercellular tight junctions. When the barrier is restored, zonulin levels decrease and are generally reversible. Individuals with various autoimmune and inflammatory disorders, including celiac disease, type 1 diabetes, and autoimmune thyroid disease, including the autoimmune atopic disease and allergic diseases, have altered levels of zonulin. Barrier dysfunction and autoimmune disease is generally associated with an inflammatory condition. The intestine is likely to be the first site of the pathogenesis of several autoimmune conditions leading to the systemic and autoimmune disease.

**1. INTRODUCTION**

In recent years much has been discussed about the structure, function, and regulation of intercellular tight junctions (TJ). However, the junctions themselves by which they separate naive cells immunologically unselected. The discovery of zonulin, a mucin-like protein (Zn), an immunoregulatory protein, indicates that the TJ is a dynamic structure that allows the TJ competency, has shed light on the immunoregulatory mechanisms involved in the modulation of the intestinal permeability barrier. Our first structural-functional analysis demonstrated that the E3/E3R1 structural protein (that we called ZO-1) of the zonulin family is a specific protein-tyrosine kinase (PTK), leading to activation of immunological signaling leading to reversible opening of intercellular TJ (17-19). These observations led to the proposal that zonulin acts as a tight, reversible, and regulatable barrier.

www.theDr.com      copyright © 2011 the American Physiological Society      133



**Premise #7**  
**How Might The Impact of Intestinal Permeability Present?**

www.theDr.com      135

**CASE STUDY #1**  
**Recurrent Miscarriages and Autoimmune Diseases**

**World J Gastroenterol 2003;9(6):1377-1380**

www.theDr.com      136      136

+CASE REPORT +

**Multiple immune disorders in unrecognized celiac disease: a case report**


George La Villa, Pedro Pariente, Roberto Serrano, Luis Ojeda, Federico Perillo, Francesco Mancuso, Giacomo Laifi  
 World J Gastroenterol 2003;9(6):1377-1380

**A 34 years old, non drinker, non smoking woman, was admitted because of hyper-amilaseamia and hyper-lipaseamia of unknown origin.**

137

**Health History (since age 3)**

- acute meningitis
- syncope, due to acute gastroenteritis complicated by metabolic acidosis
- recurrent iron deficient anemia,
- polyclonal hypergammaglobulinemia,
- recurrent elevated erythrocyte sedimentation rate (ESR),
- reduced C3 levels and circulating antinuclear antibodies (1:80) that led to suspicion of a not otherwise specified collagen disease



138

+CASE REPORT +

**Multiple immune disorders in unrecognized celiac disease: a case report**

George La Villa, Pedro Pariente, Roberto Serrano, Luis Ojeda, Federico Perillo, Francesco Mancuso, Giacomo Laifi  
 World J Gastroenterol 2003;9(6):1377-1380

**Iron deficiency was unresponsive to supplement of oral iron, while it improved following intravenous therapy.**

139

+CASE REPORT +

**Multiple immune disorders in unrecognized celiac disease: a case report**


George La Villa, Pedro Pariente, Roberto Serrano, Luis Ojeda, Federico Perillo, Francesco Mancuso, Giacomo Laifi  
 World J Gastroenterol 2003;9(6):1377-1380

**The patient had two spontaneous abortions when aged 30 and 31 years, respectively, both at the 16th week of gestation**

140

During admission because of the second abortion, a thorough investigation was performed that was negative for potential causes of fetal demise, including:


- fasting glucose,
- basal FSH, LH and estradiol levels on day 3 of a natural cycle,
- TSH and prolactin levels,
- antinuclear antibodies,
- antibodies against infectious agents,
- hysterosalpingography and genetic karyotyping of the couple



© www.theDr.com

On that occasion, she was found to have:

- hyperamylasemia and hyperlipasemia,
- anemia,
- thrombocytosis,
- high ESR,
- low plasma albumin
- high levels of IgA and IgM.
- low ferritin and tetrahydrofolate levels
- A coagulation study = + presence of lupus anticoagulant
- elevated anti-thyroglobulin and anti-b2-glycoprotein-1 antibodies




© www.theDr.com

**World J Gastroenterol**

On that occasion, she also was found to have:

- Urinalysis showed glomerular proteinuria,
- microscopic hematuria,
- hyaline and granular casts
- An IgA Nephropathy



© www.theDr.com

**World J Gastroenterol**  
2003;9(6):1377-1380

Multiple immune disorders in unrecognized celiac disease: a case report

**World J Gastroenterol 2003;9(6):1377-1380**

**Antiphospholipid antibodies, the most commonly detected of which are lupus anticoagulant, anticardiolipin and anti-b2-glycoprotein-1 antibodies, are associated with the so-called Antiphospholipid Syndrome, a syndrome of:**

- arterial and venous thrombotic disease,
- thrombocytopenia, and
- fetal wastage.

© www.theDr.com

144

Multiple immune disorders in unrecognized celiac disease: a case report

World J Gastroenterol 2003;9(6):1377-1380

**Positive anti-gliadin, anti-endomysial and anti-transglutaminase (TTG) antibodies plus a positive biopsy confirmed the diagnosis of CD. A gluten free diet was therefore introduced.**

145

Multiple immune disorders in unrecognized celiac disease: a case report

World J Gastroenterol 2003;9(6):1377-1380

**After six months of controlled gluten free diet:**

- body weight increased 12 kg
- laboratory rechecks demonstrated normalization of serum amylase, serum lipase and all immunoglobulin levels
- antigliadin, anti-b2-glicoprotein-1, anti-thyroglobulin antibodies were no longer detectable
- **but antiendomysial antibodies were still present.**
- Due to the persistence of proteinuria (2.3 g/day), microscopic hematuria and hyaline and granular casts, a kidney biopsy was positive for IgA nephropathy

146

Multiple immune disorders in unrecognized celiac disease: a case report

World J Gastroenterol 2003;9(6):1377-1380

**Repeat Endoscopy:**

- EN appearance of duodenal mucosa,
- Duodenal biopsy revealed a partial recovery of duodenal morphology.

147

**Recommendation to the patient???**

**“You’re improving. Stay the course”**

**“But Dr. It’s been SIX MONTHS”**

**“STAY THE COURSE”**



© www.theDr.com

148



Multiple immune disorders in unrecognized celiac disease: a case report  
 World J Gastroenterol 2003;9(6):1377-1380

After **24 months** of gluten-free diet:  
 -complete recovery of villous architecture.  
 -Renal function further improved and proteinuria markedly decreased.  
 -Amylase, lipase, and immunoglobulin levels were within the normal range.  
 Anti-b2-glicoprotein-1 undetectable,  
 -anti-thyroglobulin undetectable  
 -antiigliadin, antiendomysial and anti-TTG undetectable  
 -coagulation study was normal


© www.theDr.com 149

Syncope  
 Acute gastroenteritis  
 Metabolic Acidosis  
 Anemia  
 Hypergammaglobulinemia  
 Elevated ESR  
 Positive ANA  
 Positive Celiac markers  
 Low Ferritin, Low Tetrahydrofolate  
 Total Villous Atrophy and Celiac Disease  
 Positive Pancreatic Hypersecretion  
 Positive Thyroid Antibodies  
 IgA Nephropathy  
 Loss of 2 pregnancies

**CAN SUPPOSEDLY GOOD FOODS REALLY DO THIS TO ME???**

© www.theDr.com 150

Premise #8  
 When Does Autoimmune Disease Begin?



© www.theDr.com 151

MAPPING CANCER'S GENES - HOW COLOR TRICKS THE BRAIN  
 SCIENTIFIC AMERICAN  
 Will you get sick?  
 MARCH 2007  
 www.siam.com

BLACK HOLE BLOWBACK  
 Building Galactic Clusters

Digitally Memorize Your Life  
 Cleaner Diesel Engines

Molecules called predictive autoantibodies appear in the blood years before people show symptoms of various disorders. Tests that detected these molecules could warn of the need to take preventive action

© www.theDr.com 152

MAPPING CANCER'S GENES • HOW COLOR TRICKS THE BRAIN

**SCIENTIFIC AMERICAN**

BLACK HOLE BLOWBACK Building Galactic Clusters

MARCH 2007

Will you get sick?

Digitally Memorize Your Life

Cleaner Diesel Engines

© www.theDr.com

153

March 2007

Y-shaped molecules called autoantibodies in a patient's blood may tell doctors whether a patient is "brewin" a certain disease and may even indicate roughly how soon the individual will begin to feel symptoms

NEW ENGLAND JOURNAL OF MEDICINE

ORIGINAL ARTICLES

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus



NEJM:2003;349:1526-1533



ABSTRACT

Autoantibodies are typically present many years before the diagnosis of SLE. Furthermore, the appearance of autoantibodies in patients with SLE tends to follow a predictable course, with a progressive accumulation of specific autoantibodies before the onset of SLE, while patients are still asymptomatic.

© www.theDr.com

154






**Are You Developing an Autoimmune Disease Years Before Symptoms?**  
Prof. Yehuda Shoenfeld, MD, FRCP

- published more than 1,700 papers in journals such as the *New England Journal of Medicine*, *Nature*, *The Lancet*, the *Proceedings of the National Academy of Sciences of the United States*, the *Journal of Clinical Investigation*, the *Journal of Immunology*, the *Journal Blood...*
- written more than 350 chapters in books, and has authored and edited 25 books
- organized over 20 international congresses in autoimmunity
- He has educated a long list of students, over 25 students, who now hold heads of departments and institutes in medical research.


© www.theDr.com 158



**Dr. O'Bryan:** So, Professor, the question is, "When did they get lupus?" And our position has been as clinicians, the mechanism began many, many years before the symptoms ever showed.

**Is that the rationale for this world of predictive autoimmunity, to begin to identify these antibodies long before there are symptoms that have developed?**

© www.theDr.com 159




**Dr. Shoenfeld:** You have summarized it precisely. What you said has several consequences and take-home messages.

Number one is that autoimmune diseases have a long incubation time. There was this wonderful article in the well-known journal called the *New England Journal of Medicine* in which it has been found that the markers, as well as those missiles—the autoantibodies—have been detected in the blood of the patients years before the disease becomes overt clinically, the patient had, indeed, symptoms of either pains in their joints, fever, or increase in the organs due to inflammation and so forth. Sometimes the incubation time may take even 40 years.


© www.theDr.com 160





**Dr. Shoenfeld:** We have an autoimmune disease called **primary biliary cirrhosis**. The disease affects women 20 times more than men, like many of the autoimmune diseases which are more prevalent among females. However, the diseases do appear—and it's frequent—at the sixth and even seventh decade. Yet the marker, the same autoantibody, the missile, that is so specific that if you detect it incidentally, even 20 or 30 years ago, you can assure the younger woman that when she will reach the age of 60 or 70, she will develop this devastating condition called primary biliary cirrhosis.


© www.theDr.com 161



**Dr. Shoenfeld:** So it means that you need to have the missiles, the autoantibodies, in the blood for a long time before the damage accumulates in such a way that the disease becomes overt. This is called prediction of autoimmunity.

**In the past**, when students have asked me, “What would you do with a completely healthy subject in which you found such antibodies or autoantibodies like anti-DNA antibodies?” Or let's say for the sake of primary biliary cirrhosis, what is called anti-PBH antibodies. I would have said, “Leave the healthy subject alone. We treat patients. But we don't treat inflammation of the lab, **laboratoritis**.”


© www.theDr.com 162



**Dr. Shoenfeld:** Yet **what we have learned today** is that we should not neglect this incidental finding. And we should follow the patient for a long time because those who have this marker in their blood, they have a greater chance to develop a clinical disease.

Prediction is important, but it has meaning only if you can help the patient. The question is even ethical. What would you gain by just saying to the patient, “Listen, in 20 years you will develop the disease.” It's unethical.


© www.theDr.com 163



**Dr. Shoenfeld:** So we are entering into the era, not only of prediction, but we have to think about prevention. This means that we need to have drugs, research, or means by which we can clean, suppress the production of those deleterious autoantibodies before the damage will accumulate so that the patient will be clinically overt


© www.theDr.com 164






**Dr. Shoenfeld:** In some ways we do have some measurements. But I would like to refer to one of them, which is very simple, it's cheap, and it has no side effects whatsoever. And this is vitamin D.

© www.theDr.com 165




**Dr. Shoenfeld:** It has been found that vitamin D, given in large amounts—which, by the way, are completely non-toxic—can halt, can reverse, in many situations, definitely in animal models, most probably also in some human beings or in some conditions in human beings, may reduce the production of those deleterious antibodies. So we are talking not only on prediction, but we should refer more to the act and to our ability to prevent the eventual development of autoimmune diseases.

© www.theDr.com 166




**Dr. O'Bryan:** Well that is brilliantly said, and **that is the foundation of this entire summit**, is that all of our listeners understand that identifying a condition or a mechanism is of some value. But it's really, what do you do about that? And in this case, when these antibodies are identified years before there are any symptoms it gives us a window of opportunity to address some of the mechanisms, perhaps in our lifestyle, perhaps in our dietary choices, which may be contributing to some of the inflammation and some of the development of these **antibodies**.

© www.theDr.com 167



**Dr. Shoenfeld:** Yes. I just wanted very much to compliment your words because I have referred to means and measurements, and you have extended on the issue of lifestyle, and I would like to refer to it. But you are absolutely right. For instance, what we call the healthy diet, low in saturated fatty acid for instance, can change completely the picture, for instance, of systemic lupus.

© www.theDr.com 168



**Autoantibodies are messengers from the future**

“Individuals who are at risk to developing an autoimmune disease should be advised to **refrain from activities and lifestyle which endangers their health and quality of life**”

Shepshelovich D and Shoenfeld Y. Prediction and prevention of autoimmune disease: additional aspects of the mosaic of autoimmunity. *Lupus* 2006;15:183-190. [www.theDr.com](http://www.theDr.com) 169

### Predictivity of Autoimmunity

#### Systemic autoimmune diseases

Disease	Antibodies	PPV	Years before Clinical Dx
SLE	RNP, Sm, dsDNA, Ro, La, and cardiolipin antibodies	94-100%	7-10
Scleroderma	Anti-centromere antibodies Anti-topoisomerase I antibodies	100%	11
RA	Rheumatoid factor Anti-cyclic citrullinated peptide	52-88% 97%	14
Sjögren's	Anti-Ro and anti-La antibodies	73%	5
1° antiphospholipid syndrome	Anti-nucleosome antibodies Anti-cardiolipin antibodies Anti-β2 glycoprotein I	100%	11

Shoenfeld Y, Blank M, Abu-Shakra M, et al. The Mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune disease – 2008. *IMAJ* 2008;10:13-19

### Predictivity of Autoimmunity

#### Organ specific autoimmune diseases

Disease	Antibodies	PPV	Years before Clinical Dx
Hashimoto's thyroiditis *	Anti-thyroid peroxidase antibodies (postpartum)	92%	7-10
Primary biliary cirrhosis *	Anti-mitochondrial antibodies	95%	25
Type I diabetes**	Pancreatic islet cell, insulin, 65 kD glutamic acid decarboxylase, tyrosine phosphatase-like protein	43, 55, 42, and 29%	14

\* Shoenfeld Y, Blank M, Abu-Shakra M, et al. The Mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune disease – 2008. *IMAJ* 2008;10:13-19

\*\* Lindberg B, Ivarsson SA, et al. Islet autoantibodies in cord blood from children who developed Type I (insulin-dependent) diabetes mellitus before 15 years of age. *Diabetologia* 1999 42: 181-187. [www.theDr.com](http://www.theDr.com) 171

### Predictivity of Autoimmunity

#### Organ specific autoimmune diseases

Disease	Antibodies	PPV	Years before Clinical Dx
Addison's disease	Adrenal cortex antibodies	70	10
Crohn's colitis	Anti- <i>Saccharomyces cerevisiae</i> antibodies	100%	3
Celiac disease	Anti-tissue transglutaminase Anti-endomysial antibodies (HLA-DO2 or DO8 antigens)	50-60% (100%)	7

Shoenfeld Y, Blank M, Abu-Shakra M, et al. The Mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune disease – 2008. *IMAJ* 2008;10:13-19

© www.theDr.com 172

The Mosaic of Autoimmunity: Prediction, Autoantibodies, and Therapy in Autoimmune Diseases - 2008

IMAJ 2008;10:13-19

**The positive predictive value of anti-tissue transglutaminase and anti-endomysial antibodies for celiac disease onset is 50-60%**

**Key words:** autoantibodies, prediction, autoantibodies, biological therapy, autoimmune etiology, 1 regulatory cells, 2 cytokines, 3 antibodies

**Abstract:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.

**Introduction:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.

**Conclusion:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.

© www.theDr.com 173

The Mosaic of Autoimmunity: Prediction, Autoantibodies, and Therapy in Autoimmune Diseases - 2008

IMAJ 2008;10:13-19

**If the patient carries the HLA-DQ2 or DQ8 antigens, known to be genetic markers for susceptibility to celiac disease, the PPV of the autoantibodies approaches 100%.**

**Key words:** autoantibodies, prediction, autoantibodies, biological therapy, autoimmune etiology, 1 regulatory cells, 2 cytokines, 3 antibodies

**Abstract:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.

**Introduction:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.

**Conclusion:** In celiac and Crohn's disease, autoantibodies and autoantigenic epitopes are detectable with a PPV of 50% to 60% in 1 year before clinical manifestations. In rheumatoid arthritis, the rheumatoid factor has a probability of 10-15% depending on the study, while the serologic rheumatoid factor antibody the probability is much higher, reaching 70%. If the rheumatoid factor and serologic antibodies are both present, the odds are 10:1 in 1 year before patients develop the first symptoms of the disease.


© www.theDr.com 174

**Array 5 - Multiple Autoimmune Reactivity Screen**

Parietal Cell + ATPase	Intrinsic Factor	ASCA + ANCA	Tropomyosin	Thyroglobulin	Thyroid Peroxidase
21 Hydroxylase (Adrenal Cortex)	Myocardial peptide	α-Myosin	Phospholipid	Platelet Glycoprotein	Ovary + Testis
Fibulin	Collagen complex	Arthritic peptide	Osteocyte	Cytochrome P450 Hepatocyte	Insulin + Islet Cell Antigen
Glutamic-Acid Decarboxylase	Myelin Basic Protein	Asialoanglioside GM1	α + β Tubulin	Cerebellar	Synapsin


© www.theDr.com 175





**Premise #1**

**What is the Most Common Cause of Morbidity and Mortality in the Industrialized World?**



Detective Adrian Monk  
© www.theDr.com 178


NIH, Autoimmune Diseases Coordinating Comm.  
Autoimmune Diseases Research Plan, 2006

**While many individual autoimmune diseases are rare, collectively they are thought to affect approximately 8 percent of the United States population – 24 million persons.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
© www.theDr.com 179

**Premise #2**


**Genes Control Function**



Detective Adrian Monk  
© www.theDr.com 180




**Premise #3**  
**Food Turns On and Turns OFF Our Genes**




Detective Adrian Monk  
© www.theDr.com 181

**Premise #4**  
**Where Does the Persisting Inflammation Come From?**




© www.theDr.com 182

**Premise #5**  
**What is the Impact of Intestinal Permeability?**



© www.theDr.com 183




Premise #6

What is the Mechanism of Intestinal Permeability?



185



The pathways of antigen invasion through Transcellular and Paracellular routes.

186

Premise #7

How Might The Impact of Intestinal Permeability Present?



© www.theDr.com





187

Premise #8


Immunological Markers in Screening for Antigenic Intestinal Permeability

Mucosal Immunology Vol 3 No 3 | MAY 2010  
Neuroendocrinology Letters Volume 29 No. 1 2008  
J Affect Disord. 2007 Apr;99(1-3):237-40 © www.theDr.com  
Neuro Endocrinol Lett. 2007 Dec;28(6):739-44.

188



**Premise #10**  
**How Might The Impact of Intestinal Permeability Present?**



© www.theDr.com 193

**CASE STUDY #1**

**Recurrent Miscarriages and Autoimmune Diseases**


J Neurochem. 2011 Nov;119(4):826-38

© www.theDr.com 194 194

**Try Something Different**



© www.theDr.com 195



**Take Care of Yourself**

© www.theDr.com 196



**Make Sure to Tell those Important to You  
How Much You Love them**



© www.theDr.com

197

# GENETIC NUTRITIONEERING

*How You Can Modify Inherited Traits  
and Live a Longer, Healthier Life*

*"Throughout your life the most profound influences on your health, vitality and function are not the Doctors you have visited or the drugs, surgery, or other therapies you have undertaken. The most profound influences are the cumulative effects of the decisions you make about your diet and lifestyle on the expression of your genes."*

**JEFFREY S. BLAND, PH.D.**

© www.theDr.com  
**WITH SARA H. BENUM, M.A.**

198


*"Thank You for Your Kind Attention"*



© www.theDr.com

199

*Wishing you Sunrises of Beauty throughout your life*



© www.theDr.com

200

